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Tuberculosis remains a major global health problem by caus-
ing ill-health among millions of people each year and ranking
as the second leading cause of death from an infectious disease
worldwide [1]. The latest estimates were almost 9 million new
tuberculosis cases and 1.4 million tuberculosis-related deaths
in 2011 [1]. It has been well established that both innate and
adaptive immune responses are required for host control of
tuberculosis infection [2,3]. In tuberculosis pathogenesis, the
host cellular immune response determines whether an infection
is arrested as latent or persistent infection or progresses to the
next stages, active tuberculosis infection. Efficient cell-medi-
ated immunity hinders tuberculosis infection by permanently
arresting the infection at latent or persistent stage, but if the
initial infection in the lung is not controlled or if the immune
system becomes weakened, Mycobacterium tuberculosis can
cause active pulmonary or extra pulmonary tuberculosis [4].
Therefore, it is expected that the genetic variants of molecules
involved in innate host-defense mechanisms are associated
with host susceptibility to tuberculosis [5].
Approximately 90% of tuberculosis-infected individuals
will remain asymptomatic with latent infection and only
10% will develop active disease, again, suggesting that host ge-
netic factors play an important role to regulate the progression
of tuberculosis infection [5]. Differential rates of tuberculosis
infection and clinical outcomes among races, ethnicities, and
families suggest a plausible genetic contribution toward tuber-
culosis susceptibility [6]. Complex interactions ofM. tuberculo-
sis with environmental and host genetic factors play a criticalrole in tuberculosis infection [6]. Several genomic studies dem-
onstrate that host genetics strongly influence tuberculosis sus-
ceptibility [7–10]. Unraveling the mechanisms underlying the
genetic variations that influence the susceptibility or resistance
to tuberculosis may lead to better understanding tuberculosis
pathogenesis and the development of novel strategies for pre-
vention and treatment of tuberculosis [5].
Assessing the contributions and functional consequences of
human genetic polymorphisms to tuberculosis susceptibility or
disease progression remains a major challenge. In previous
publications, our group has discussed the role of human genet-
ic polymorphisms in sepsis and dengue virus infection [11–13].
Here, we will review the implications of specific human genetic
polymorphisms related to susceptibility and severity of tuber-
culosis infection.
Discussion
Natural resistance-associated macrophage protein 1
(NRAMP1)
NRAMP1 is located on the endocytic compartment of resting
macrophages and is recruited to the membrane of the phago-
some depending on the pH gradient [14]. NRAMP1 acts as a
divalent cation transporter or antiporter across phagosomal
membranes that is expressed only in reticuloendothelial cells
[6,15]. These facts suggest that NRAMP1 may inhibit the rep-
lication of intracellular pathogens by altering the phagolysos-
omal environment. NRAMP1 is a critical mediator in the
innate immune response to tuberculosis infection which leads
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in M. tuberculosis [16], but the precise function of this protein
remains unclear [6]. Several polymorphisms have been de-
scribed in the NRAMP1 gene and these polymorphisms alter
the gene’s function [17]. Four NRAMP1 polymorphisms; 30-
UTR, D543N, 50(GT)n, and INT4 have been associations with
M. tuberculosis infection in humans [6]. In terms of the
50(GT)n polymorphism, a study found that there was a signif-
icant association of this NRAMP1 polymorphism type with
tuberculosis when considering an interaction with Toll-like
receptor 2 (TLR2) [17]. Most of the variants’ associations were
established in a meta-analysis of China populations [18]. An-
other study found that NRAMP1 polymorphisms at the
D543N and INT4 loci contribute to severe pulmonary tubercu-
losis [19]. However, NRAMP1 polymorphisms at the D543N
and INT4 were not associated with tuberculosis in an Indone-
sian population [14].Toll-like receptor 2 (TLR2)
TLRs are transmembrane molecules that serve as sentries for
pathogen detection, by a kind of evolutionary recognition of
molecular patterns associated with past infections [20]. TRL
expression found in many cell types, including host immune
cells, serves as critical mediators of the immune response to
a variety of pathogens, including M. tuberculosis [21]. Several
types of TLRs have strong links with tuberculosis, including
TLR1, TLR2, TLR4, TLR6 and TLR9. The genetic variant
most often associated with tuberculosis is found in TLR2 [6].
A TLR2 heterodimer, in combination with the TLR1, binds
19-kD mycobacterial lipoprotein, suggesting TLR2 is an adhe-
sion molecule for M. tuberculosis [22]. A previous study sug-
gests that Toll interleukin 1 receptor domain containing
adaptor protein (TIRAP), an adaptor that mediates signals
from TLRs activated by mycobacterial molecules, induced a
strong proinflammatory response to tuberculosis [6]. Studies
in animal and human revealed that TLRs play pivotal roles
in innate immune response to tuberculosis via many pathways
(a) TLR activation triggers a complex of cascade that leads to
induction of a large range of proinflammatory genes [23]; (b)
TLRs activate nuclear factor j beta (NFjB) which is the first
line of defense against many pathogens [24]; (c) TLRs play
integral roles in the activation of inflammatory cytokine signal-
ing pathways and adaptive immune responses [25].
A number of reports found SNPs in TLR2 gene that affect
tuberculosis susceptibility, including R753Q (exon), R677W
(exon), 597T/C and P631H [26–28]. TLR2 R753Q influ-
enced tuberculosis progression in children [27] and TLR2
597T/C strongly associated with miliary tuberculosis [28].
Another study found that TLR2 975C/T was associated with
protection against tuberculosis, resultant from attenuation of
TLR2 signal transduction [29]. Moreover, a microsatellite re-
gion within intron 2 of TLR2, TLR 975C/T, has significant
frequency variation across populations and may also influence
gene function [28]. In a Korean population, a study found an
association between this SNP and pulmonary tuberculosis [30].
The possible reason is the C allele has a high level of linkage
with the allele of the GT microsatellite that affects TLR2 gene
regulation. Another TLR2 SNP, TLR2 P631H, was signifi-
cantly over-represented in tuberculosis patients compared to
controls in a Croatian Caucasian population [31]. Theseevidences suggested that TLR2 gene SNPs likely play impor-
tant roles in tuberculosis infection.
Interleukin-6 (IL-6)
IL-6, a mayor mediator of fever and acute-phase reactions, is
expressed in hepatocytes, monocytes, B cells lymphocytes,
macrophages, and neutrophils in humans [11]. It is also found
on a subset of T-cell lymphocytes [32]. As a key proinflamma-
tory cytokine, IL-6 is associated with the pathogenesis of many
chronic inflammatory diseases, including tuberculosis [33].
Briefly, IL-6 is likely to be associated with several tuberculo-
sis-related roles: (a) IL-6 blocks interferon (IFN)-c mediated
signaling; (b) IL-6 downregulates IL-6 receptor (IL-6R)
expression in CD4 T-cells and is associated with T-helper cell
depletion; (c) IL-6 induces IL-4 production; and (d) IL-6 is in-
volved in macrophage and cytotoxic T-cell differentiation
[6,34,35].
Genetic variants in IL-6 have been linked to susceptibility
and severity of a wide range of diseases, including chronic hep-
atitis C virus infection and respiratory tract infection [36,37].
In an animal model study, IL-6 is required for rapid expression
of an initial protective IFN-c response during M. tuberculosis
infection [35]. In humans, a higher level of IL-6 may be detri-
mental to resistance against M. tuberculosis infection [38]. A
genome-wide scan of Ugandans with tuberculosis revealed a
linkage to a locus on chromosome 7 which contains the IL-6
gene [39]. Zhang et al. [38] reported that the nonsynonymous
SNP in the IL-6 gene promoter 572C > G is associated with
higher resistance to tuberculosis. They also found that
572GG genotype contributed to protection against tubercu-
losis in the Han Chinese population through downregulation
of IL-6 production. Another SNP, the G allele or GG geno-
type in the IL-6 gene promoter region (174), was associated
with high IL-6 production [34,40] in tuberculosis patients
which may have promoted tuberculosis by inhibiting other
cytokines production such as tumor necrosis factor (TNF)
and IL-1b [6].
Tumor necrosis factor alpha (TNF-a)
TNF-a is an important proinflammatory cytokine, which is
produced primarily by monocytes, macrophages, and dendritic
cells when stimulated by mycobacterial metabolites; therefore,
TNF-a is likely involved in host protective responses against
M. tuberculosis infection [6]. TNF-a also has immunoregula-
tory properties and synergistic effects to IFN-c in macrophage
activation [41]. However, systemic excess of TNF-a may ac-
count for unwanted inflammatory effects like fever and malaise
[41]. Briefly, there are many effects of TNF-a on the host
immunological response to M. tuberculosis infection. Neutral-
ization of TNF-a causes persistent tuberculosis reactivation,
characterized by an increase of tissue bacillary burden and
severe pulmonic histopathological deterioration that was asso-
ciated with changes indicative of squamous metaplasia and
fluid accumulation in the alveolar space. In addition, analysis
of pulmonic gene and protein expression in mice revealed that
nitric oxide syntheses were attenuated after TNF-a neutraliza-
tion [42].
The TNFA gene, which encodes cytokine TNF-a, is located
within the major histocompatibility complex (MHC) between
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genes region at the short arm of chromosome 6. The produc-
tion of TNF-a is both transcriptionally and post-transcription-
ally regulated [43]. Some SNPs in the TNFA gene substantially
regulate TNF-a production by regulating its transcription,
including eleven SNPs in promoter region 1031 (T/C),
863 (C/A), 857 (C/T), 308 (G/A), 238 (G/A), 1196
(C/T), 1125 (G/C), 572 (A/C), 316 (G/A), 163 (G/A),
and 70 (G/A) [44,45]. In clinical studies, the most common
SNP in the TNFA promoter region is TNFA 238G/A
#CITATION; however, the associations between this SNP
and tuberculosis remain unclear. Amirzargar et al. found a
negative association between the 238G/A genotype and
tuberculosis; however, G/G genotype had a positive associa-
tion [40]. Previously, a study identified a significant association
between TNFA 238G/A and tuberculosis susceptibility [46].
However, another study found that the TNFA 238G/A SNP
allele did not associate with tuberculosis [47]. Additionally, a
study in Iran documented that the SNP TNFA 857C/T in-
creased the host susceptibility to tuberculosis infection [48].
These contradictory results underscore the need to establish
the associations of TNFA genotypes with tuberculosis clinical
outcomes in different human populations.
Interleukin-1 receptor antagonist (IL-1RA)
The IL-1 family consists of IL-1 alpha (IL-1a), IL-1 beta (IL-
1b), and IL-1RA. IL-1a and IL-b bind to the IL-1 receptor
(IL-1R) and initiate an inflammation cascade to induce vascu-
lar dilation and fever [11]. IL-1RA is a competitive inhibitor of
IL-1 to induce proinflammatory activity. The IL-1RA gene is
polymorphic, resulting in quantitative differences in IL-1RA
and IL-1b production [48]. The polymorphic region within in-
tron 2 of the IL-1RN* gene contains a 86-bp variable numbers
of tandem repeats (VNTR) locus. Five alleles of the IL-1RN*
VNTR have been reported (*1–*5), corresponding to 2, 3, 4, 5
and 6 copies of the 86-bp sequence, respectively [11]. A previ-
ous study investigated the effect of polymorphisms in the IL-
1Ra genes onM. tuberculosis – stimulated cytokine production
in vitro and their relevance in patients with tuberculosis [49]. It
was reported that induction of both IL-1Ra mRNA and a se-
creted protein by M. tuberculosis in IL-1Ra allele A2–positive
(IL-1Ra A2+) of healthy subjects was higher than in IL-1Ra
A2 subjects. In addition, the IL-1Ra A2+ haplotype was
associated with a reduced Mantoux response. This study con-
firmed that the IL-1RA polymorphism was a determinant of
delayed-type hypersensitivity and disease expression in the hu-
man immune response.
The IL-1RA A2+ variant is associated with higher serum
levels of IL-1RA [48]. Therefore, being IL-1RA A2+ homozy-
gous has a more prolonged and more severe proinflammatory
immune response. The IL-1RA A2+ genotype was also associ-
ated with a reduction in the delayed type hypersensitivity re-
sponse to purified protein derivative and was inversely
related to the development of pleural tuberculosis [48].
Interleukin-10 (IL-10)
IL-10, a major anti-inflammatory cytokine associated with sev-
eral diseases, is an important immunoregulatory mediator pro-
duced by activated monocytes/macrophages, dendritic cells, Tand B lymphocytes [50]. IL-10 production in human monocyte
cells is induced byM. tuberculosis phagocytosis, but IL-10 also
suppresses the proinflammatory response by downregulating
cytokine production; therefore, IL-10 is considered a macro-
phage-deactivating cytokine [51]. However, IL-10 potentially
helpsM. tuberculosis persistence in humans by inhibiting phag-
osome maturation in macrophages [52]. In mice, IL-10 pro-
duced by macrophages was higher in mice that had been
stimulated with purified protein derivative of M. tuberculosis
than in wild type resistant mice. Moreover, M. tuberculosis
activated TNF-a and IL-10 – dependent signals that induce
apoptosis in mice [53]. Many IL-10 gene SNPs have been de-
scribed in previous studies, including 1082G/A (promoter)
and 592A/C (promoter) [6,54–56]. A review by Azad et al.
found that IL-10 promoter SNPs play a significant role in
M. tuberculosis infection [6]. IL-10 1082G/A and 592A/C
have been associated with higher IL-10 protein expression
[55]. Despite many studies establishing associations between
these SNPs and tuberculosis, other studies reported that these
SNPs had no association with tuberculosis [54,56–60]. In a
candidate gene linkage study using microsatellite markers,
the IL-10 gene was implicated in clinical tuberculosis [61]. This
study found a strong association between IL-10 microsatellite
polymorphisms, TNF levels and tuberculosis. A study in Gam-
bia investigated that NRAMP1 influenced tuberculosis suscep-
tibility by regulation of IL-10 [53]. They also found that IL-10
plasma levels measured higher among tuberculosis patients
compared with the control group. Higher IL-10 levels could
lead to tuberculosis development via two different mecha-
nisms: (a) IL-10 controls M. tuberculosis infection through
macrophage up-regulation and production of microbicidal
compounds, including reactive oxygen and nitrogen intermedi-
ates, and TNF-a. (b) IL-10 regulates secondary immune re-
sponse development in tuberculosis. Based on the reported
results, manipulation of the IL-10 pathway may be a novel
immunotherapy for tuberculosis treatment in the future.
Vitamin D receptor (VDR)
The VDR gene encodes a transcription factor, when activated
by vitamin D, modulates diverse biologic processes, including
calcium homeostasis and immune function. VDR mediates the
immunoregulatory effects of 1,25-dihydroxyvitamin D3
(1,25D3), which activates monocytes, stimulating cellular im-
mune responses and suppressing immunoglobulin production
and lymphocyte proliferation [11]. Genetic variation in VDR
shows striking differences in allele frequency between popula-
tions and has been associated with disease susceptibility,
including autoimmunity disorders and tuberculsosis [62]. Sev-
eral VDR polymorphisms have been identified, namely TaqI
(TT, Tt and tt), ApaI (AA, Aa and aa) and BsmI (BB, Bb
and bb) [63]. Recent studies suggested a protection association
between VDR polymorphisms and infectious diseases includ-
ing tuberculosis, Leishmania major, Human Immunodefi-
ciency Virus (HIV), dengue hemorrhagic fever and
Staphylococcus aureus infection [63–67]. These associations
led to the suggestion that the tt genotype may be associated
with a relatively stronger TH1-type cellular immune response
than the TT genotype; interestingly, 1,25D3 has been found
to alter IL-12 expression and dendritic cells maturation [68].
A previous study found that the tt genotype was less frequent
in patients with pulmonary tuberculosis in Gambia [69].
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the association between VDR haplotypes and tuberculosis
infection [70].
Vitamin D has been linked to tuberculosis pathogenesis
through VDR action [71,72]. It suppressed M. tuberculosis
growth in macrophages through induction of antimicrobial
peptide cathelicidin and likely via the TLR signaling [71–73].
Several VDR polymorphisms with nomenclature derived from
their restriction enzyme cleavage sites, such as FokI, TaqI,
BsmI, and ApaI, and their combination as a haplotype, have
been tested in population studies for tuberculosis associations
[74]. A study investigated the role of FokI, BsmI, ApaI, and
TaqI VDR gene polymorphisms on child tuberculosis in Indo-
nesian populations [75]. This study documented that FokI var-
iant was more frequently found in the tuberculosis group than
the control group, while BsmI, ApaI, and TaqI variants did
not differ significantly between the tuberculosis and control
group. This study suggested that the FokI variation is a risk
factor for child tuberculosis. However, a study in Turkey
found that there was no correlation between FokI and TaqI
frequencies with tuberculosis infection but the BsmI variation
might play an important role in tuberculosis susceptibility [76].
Another study in West African populations reported that ApaI
had a significant association with tuberculosis, suggesting
ApaI variation as a potential risk factor for tuberculosis [77].
A meta-analysis by Gao et al. found inconsistent results [74].
They found that among the Asian population, the FokI ff
genotype showed an association with tuberculosis, a significant
inverse association with tuberculosis was observed for the
BsmI bb genotype. However, in African and South American
populations, none of the VDR gene polymorphisms were sig-
nificantly related to tuberculosis. Andraos et al. reported a
complex association between VDR gene methylation and the
TaqI genotype, which highlighted the need to consider how
both genetic and epigenetic variation associates with tubercu-
losis [62]. The variation in VDR gene methylation, and its im-
pact on VDR expression and tuberculosis susceptibility remain
to be determined.
Dendritic cell-specific ICAM-3-grabbing non-integrin (DC-
SIGN)
DC-SIGN, a C-type lectin encoded by the CD209 gene, plays
an important role in the early interaction of pathogens with
dendritic cells and has a key role in dendritic cell T-cell
interaction, dendritic cell migration, and pathogen uptake
[11]. DC-SIGN is a type II transmembrane protein predomi-
nantly expressed in dendritic cells that are induced in alveolar
macrophages from M. tuberculosis-infected patients [6]. It
directly mediates phagocytosis of M. tuberculosis by dendritic
cells and interferes with dendritic cells maturation [78,79].
Some polymorphisms in the DC-SIGN gene have been re-
ported, two of these polymorphisms, DC-SIGN 336A/G
and 871A/G, occur within DC-SIGN promoter [11]. These
variants affect DC-SIGN promoter activity with multiple tran-
scription factor binding sites [80]. Some studies documented
that these variants have been associated with bacterial and vir-
al infection [79,81]. Previous study suggests that DC-SIGN
336A/G and 871A/G had significant associations with
tuberculosis infection [82]. Recently, a study investigating the
associations between DC-SIGN 336A/G and 871A/G andtuberculosis susceptibility in an Eastern Chinese population
did not associate the DC-SIGN variation with tuberculosis
susceptibility [83]. However, DC-SIGN 336A/G and
871A/G genotypes were shown to have protective associa-
tions against tuberculosis in a South African population [84].
Additionally, in a Chinese population, the G allele at 336
had a significant association with tuberculosis protection
[83]. The DC–SIGN 336G allele affects an Sp1 binding site
and decreases DC–SIGN expression resulting in less efficient
cytokine and chemokine secretion [85]. Polymorphisms within
the 50- and 30-UTRs of both DC-SIGN and DC-SIGN recep-
tor (DC-SIGNR), presumably affecting transcription and
translation, have possible associations with tuberculosis sus-
ceptibility in both Caucasian Canadian and indigenous Afri-
can populations [6].
Monocyte chemoattractant protein-1 (MCP-1)
The human MCP-1 gene is located on chromosome 17, con-
sists of 76 amino acids and is 13 kDa in size [86,87]. MCP-1,
a member of the C–C chemokine family, has a role as potent
chemotactic factor for monocytes, which play critical roles in
recruitment of macrophages and T lymphocytes for controlling
M. tuberculosis dissemination [88,89]. Numerous studies inves-
tigated the association of MCP-1 genetic variants and tubercu-
losis susceptibility [86,89–91].
The MCP-1 2518A/G functional SNP, locates on the pro-
motor region and plays a key role in various pathologie [6].
MCP-1 2518A/G affects the transcriptional activity of the
distal regulatory region, and modulates monocyte MCP-1 pro-
duction [90]. Compared with the MCP-1 2518A allele, the
MCP-1 2518G allele was associated with higher MCP-1 pro-
tein production in monocytes. Additionally, higher levels of
MCP-1 increase the protective effects against tuberculosis
infection [92]. Moreover, an in vivo study further suggests that
low levels of MPC-1 in mice impaired granuloma formation
and conferred lower tuberculosis susceptibility [92].
Population-based studies have reported an association be-
tween MCP-1 2518A/G with risk of tuberculosis, but the re-
sults were inconclusive. Some studies reported that MCP-1
2518A/G was associated with increased risk of tuberculosis
in Mexicans, Koreans, Chinese and Peruvians, while other
studies fail to establish an association between this SNP and
tuberculosis infection such as in South African Coloreds, Indi-
ans, and Ghanaians [85,90,93–95]. Interestingly, Ben-Selma
et al. found an association between MCP-1 2518A/G with
resistance/susceptibility of active pulmonary tuberculosis
development in Tunisian populations [88]. This group also ob-
served that the MCP-1 2518G allele and GG genotype (high
MCP-1 producer) frequencies were significantly higher in the
active pulmonary tuberculosis group than the control group.
However, wild type allele MCP-1 2518A and AA genotype
were over represented in the control group and seem to be pro-
tective factors against tuberculosis. Recent study also indicated
that GG homozygote carriers had a higher risk of tuberculosis
compared to individuals with an A allele [87]. In the subgroup
analysis by ethnicity for this locus, a highly significant risk was
found in Asians and Latinos with the GG genotype, but not in
Africans. Other studies also confirmed that MCP-1 2518GG
genotype associated with tuberculosis outcome and resistance
[86,91].
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NOD2 is a member of the conserved nod-like receptor (NLR)
protein family that acts as an intracellular pattern recognition
receptor (PRR) [96]. NLR family proteins share typical tripar-
tite domain structure: a C-terminal ligand recognition domain
(LRR), a central NOD domain with ATPase activity involved
in self-oligomerization and a N-terminus comprised of pro-
tein–protein interaction domains, such as caspase recruitment
domains (CARDs) or pyrin domains [96,97]. Expression of
NOD2 is regulated by proinflammatory cytokines, for instance
TNF-a positively regulates its expression and is augmented by
IFN-c [98]. In tuberculosis pathogenesis, C-terminal protein
domain of NOD2 and C-terminal LRR domain have a crucial
role in membrane targeting, which could detect the component
of M. tuberculosis cell wall, such as derived-peptides of pepti-
doglican (PGN) degradation and recognizes muramyl dipep-
tide (MDP), a component of PGN [99].
Polymorphisms of NOD2 gene have been associated with
increased risk of pulmonary sarcoidosis and leprosy
[100,101]. Recently, a review by Azad et al. showed three com-
mon non-synonymous SNPs of the NOD2 gene play impor-
tant roles in tuberculosis, including Pro268Ser, Arg702Trp,
and Ala725Gly [6]. A population-based study sequenced exon
4 coding regions of NOD2 gene in African-Americans with
tuberculosis and ethnically matched controlled subjects [102].
This study found that Pro268Ser and Arg702Trp variations
were protective against tuberculosis and Ala725Gly had a po-
sitive association with tuberculosis susceptibility. However,
there was no association found between these polymorphisms
and tuberculosis infection in a South African population study
[103]. Recently, one case control study investigated the role of
NOD2 gene SNPs in the tuberculosis susceptibility of Han
Chinese, Uygur and Kazak populations [105]. This study
found that the Arg587Arg SNP in NOD2 associated with sus-
ceptibility to tuberculosis and may be a risk factor for the
development of tuberculosis in the Han Chinese populations.
However, further work will be required both to confirm this
association and to explore possible mechanisms.
Another experiment showed that polymorphisms of NOD2
associated with tuberculosis [104]. Macrophages from NOD2
knockout mice produced a significantly lower level of cyto-
kines than control cells did. This group also found that macro-
phages isolated from human subjects homozygous for the
3020insC mutation of NOD2 produced 65–80% fewer cyto-
kines after stimulation with M. tuberculosis than individuals’
heterozygous or homozygous for the wild-type genotype. The
NOD2 ligand MDP had a strong synergistic effect on TNF
production induced by TLR2 ligand, the 19-kDa lipoprotein
of M. tuberculosis. This synergism was lost in individuals’
homozygous for NOD2 3020insC mutation or macrophages
harvested from NOD2 knockout mice.Interferon-gamma (IFN-c)
IFN-c is a member of the INF family which plays a crucial role
in the reaction of the immune system in resistance to patho-
gens such as M. tuberculosis [106]. IFN-c is produced by nat-
ural killer (NK) cells, characterizes the T helper 1 (Th1)
pattern, and has a wide range of effects including monocyte
and macrophage activation [107]. The Th1 cell response, whichis required to containM. tuberculosis infection, is largely char-
acterized by IFN-c production [106]. Furthermore, IFN-c and
other cytokines can activate macrophages in vascular endothe-
lium and promote plasma extravasations [11]. Convincing evi-
dence for the importance of IFN-c to control M. tuberculosis
infection has been found in both experimental and clinical
studies. Mice with a disrupted IFN-c gene (IFNG) show in-
creased susceptibility to tuberculosis and replacement of this
gene into the lung confers resistance [108,109]. In most tuber-
culosis patients the production of M. tuberculosis-induced
IFN-c by peripheral blood mononuclear cells is reduced at
the time of diagnosis. During and after successful treatment,
these levels increase significantly [106]. Although IFN-c is re-
quired for an initial protective Th1 cell response toM. tubercu-
losis, the increased production of this cytokine post-infection is
indicative of the risk of developing active tuberculosis. A re-
cent study showed that macaque monkeys with high IFN-c
levels two months post infection with M. tuberculosis were
more likely to develop active tuberculosis and similar observa-
tions have been made in humans [110,111]. Humans with
mutations in genes of the IL-12/IL-23/IFN-c axis have an in-
creased susceptibility to even nonpathogenic tuberculosis and
are extremely susceptible to M. tuberculosis and Salmonella,
but not to other bacteria [112].
An SNP in intron 1 of IFNG, IFNG+ 874A/T, associates
with tuberculosis development in several populations, includ-
ing Sicilians, South Africans, Hong Kong and Chinese, and
Spanish [57,113–115]. However, study in Malawians, Houston,
West Africa, and South India failed to demonstrate an associ-
ation between this SNP and tuberculosis development [116–
119]. Recently, a study showed that the IFNG+ 874A allele
frequency was higher in patients with tuberculosis than in
healthy individuals and had a significant association with sus-
ceptibility to tuberculosis in an Iranian population [123]. In
addition, a meta-analysis reported a protective effect of the
+874T allele against the development of tuberculosis [58].
The genotype IFNG 56CC in the promoter region and the
cytosine-adenine repeat polymorphism on intron 1 were re-
ported to be associated with tuberculosis development
[118,120]. Etokebe et al. conducted a study to confirm the asso-
ciations between INFG SNPs (T + 874A and G+ 2109A)
and tuberculosis infection in Croatia [121]. They found that
these SNPs did not associate with tuberculosis infection; how-
ever, they suggested that the presence or absence of these SNPs
could provide useful information on public health decision
such as the duration of patient isolation as well as the clinical
course of treated tuberculosis patients. These SNPs may be a
diagnostic test in tuberculosis cases [122].Inducible nitric oxide synthase (iNOS)
The Nitric oxide synthase (NOS) gene, present on the human
chromosome 17q11.2–12, transcribes NOS enzymes that cause
the oxidative deamination of amino acid L-arginine to form ni-
tric oxide (NO). There are three isoforms of NOS enzymes:
neuronal nitric oxide synthase (nNOS), endothelial nitric oxide
synthase (eNOS) and inducible nitric oxide synthase (iNOS)
[124]. iNOS (also known as NOS2 and encoded by human
NOS2A), was expressed by mycobacterium-infected macro-
phages and epithelial cells, an effectors’ molecule with bacteri-
cidal activity against M. tuberculosis [6,125]. In pulmonary
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to infections with bacteriostatic processes. The alveolar macro-
phages induced by M. tuberculosis are capable of producing
TNF-a and IL-1. These cytokines along with IFN-c produced
by T-cells can induce NO synthesis via action of iNOS. Thus,
NO and radical nitrogen intermediate can inhibit intracellular
mycobacterium pathogens [124].
Genetically, the action of iNOS in the immune system is
well known, SNP variation in the promoter region has been
implicated in several diseases including bacterial meningitis,
HIV and hepatitis C virus [126–128]. These associations led
to the suggestion that the presence of polymorphisms in pro-
moter regions transcriptionally deregulate the iNOS gene,
altering the level of gene product. SNPs in coding regions of
exon 16 alter the activity of iNOS gene product. Alteration
in the level and activity of iNOS might be responsible for the
susceptibility, severity and outcome of genetic as well as infec-
tious disease [124]. Beisiegel et al. investigated combinations
such as, challenging inducible nitric oxide synthase – deficient
(iNOS/) and wild-type mice with two related M. tuberculo-
sis strains that differ markedly in virulence. They found that
the combination of host susceptibility and M. tuberculosis vir-
ulence determines the role of iNOS in the protection and con-
trol of inflammation [129].
Several allele/polymorphisms in the iNOS gene have been
reported in many populations, including CCTTT and TAAA
in Columbia, 1026G allele in Brazil, rs2274894 (intron) and
rs7215373 (30-UTR) in African-American and 954G/C in
Mexican populations [130–132]. However, not all of these
polymorphisms have associations with tuberculosis infection.
In Northwestern Colombian populations, the genotype fre-
quencies for iNOS CCTTT differ significantly between tuber-
culosis patients and controls, but no individual association
with iNOS TAAA was detected [130]. In Mexicans, the iNOS
954G/C SNP was not associated with tuberculosis infection
[133]. Interestingly, this SNP has a significant association with
tuberculosis susceptibility in a Brazilian population [131].
These incongruent associations further suggest that more
research is needed to better understand genetic variation
underlying iNOS-related clinical phenotypes in admixed
populations.
Mannose-binding lectin (MBL)
MBL is an acute phase protein secreted by the liver, which
mediates carbohydrate dependent activation of the classical
complement pathway [6,11]. Moreover, MBL plays an impor-
tant role in pattern recognition and innate immune defense
[134]. Briefly, host defense mechanisms against M. tuberculosis
use MBL in many pathways: (a) MBL acts as opsonin; (b)
MBL enhances both complement dependent and independent
phagocytosis; (c) and MBL promotes inflammation and re-
leases cytokines [135,136].
In a prospective study, the levels of MBL protein were
found to be higher in tuberculosis patients than in healthy con-
trol [137]. However, a study examining the role of the comple-
ment system in protection against respiratory tract infection
indicated an important pathway of the complement system
controls respiratory tract infection and potential influences
tuberculosis severity in humans. Soborg et al. found a positive
association between MBL concentration in human serum andthe level of M. tuberculosis neutralizing activity, which indi-
cated low levels of MBL protein or its activity as an indepen-
dent risk factor for tuberculosis infection morbidity and
mortality [138].
Three structural mutations, affecting codons 52, 54, and 57,
in the first exon of MBL2 gene have been found, and the cor-
responding alleles were designated D, B, and C, respectively (A
is the wild-type allele for all three positions) [139]. Mutations
at these codons result in low or nearly absent serum MBL lev-
els in hetero- or homozygote individuals. However, the study
with MBL alleles, genotypes, or haplotypes, based on these
polymorphisms; has yielded conflicting results [140].
Mutation in the MBL promoter region has also been re-
ported [139]. Some studies found significant associations be-
tween MBL2 promoter polymorphisms, serum MBL levels
and tuberculosis susceptibility, while another study did not
find any significant association [140–143]. According to a case
control study in a Spanish population, the MBL D variant and
HYPD haplotype were significantly more frequent in controls
than in tuberculosis cases. This result indicates that these al-
leles could contribute toward protection against pulmonary
tuberculosis development. However, high MBL levels appear
to correlate with several diseases [144]. Individuals with differ-
ent levels of MBL2 due to known polymorphisms in the MBL2
gene demonstrated a positive correlation between human
MBL2 levels and neutralization of M. tuberculosis [137]. This
result linked together subsequent findings related to humans
with particular polymorphisms in the MBL2 gene which sug-
gested that the MBL pathway contributes to protection against
M. tuberculosis infection in humans [145].
Surfactant proteins A (SP-A)
SP-A is predominantly expressed by lung alveolar type II epi-
thelial cells and non-ciliated cells. SP-A is a hydrophilic pro-
tein consisting of a collagen like domain in the N terminus
that mediates oligomerization, a coiled-coiled area, and a glob-
ular Ca-dependent carbohydrate recognition domain at the C
terminus [148]. The human SP-A locus has been mapped in
chromosome region 10q22-q23 and consists of two highly sim-
ilar isoforms encoded by separate genes, SP-A1 and SP-A2
[6,147]. SP-A plays an important role in pattern recognition
and the innate immune system with the ability to bind exposed
carbohydrate residues on the surface of M. tuberculosis and
regulates the macrophage expression and the function of
TLR2 and -4 [4,146]. Previously, in vitro studies showed that
SP-A could modulate the anti-tuberculosis response by con-
tributing to bacterial agglutination that can enhanceM. tuber-
culosis association with alveolar epithelium [148,149]. This
agglutination, however, was not associated with bacterial kill-
ing, since SP-A signaling has also been reported to reduce the
production of reactive nitrogen and oxygen intermediates
[146,150].
Several synonymous and non-synonymous SNPs have been
identified in the SP-A1 and SP-A2 genes, including 1416C/T
(intron), 1382C/G (intron) 307G/A (exon), 776C/T
(exon), 355C/G (exon) and 751A/C (exon) [147–151]. SP-
A1/2 alleles have been shown to be associated with infectious
pulmonary disease, including respiratory syncytial virus infec-
tion and pulmonary tuberculosis [147,152–154]. In an Indian
population, seven SNPs (4 exonic and 3 intronic) have been
180 S.A. Khalilullah et al.identified in collagen regions of SP-A1 and SP-A2 genes [151].
Two intronic SNPs, 1416C/T and 1382C/G, showed signif-
icant association with pulmonary tuberculosis. This study also
found that a redundant of SP-A2 gene SNPs showed signifi-
cant association with pulmonary tuberculosis. These data rep-
licate previous findings in a Mexican tuberculosis cohort [153].
Several intronic and exonic SP-A1 and SP-A2 SNPs, which af-
fect splicing and/or mRNA maturation, had associations with
tuberculosis [147]. This study also suggested that SP-A1 and
SP-A2 SNPs influence the production of TNF-a and IL-8 in
THP-1 cells. Furthermore, alleles in the SP-A1 and SP-A2
genes also influence the ability of SP-A to self-aggregate and
to induce lipopolysaccharide aggregation, which is consistent
with an inflammatory role of SP-A [155]. Thus, SP-A1 and
SP-A2 may be contributing factors to susceptibility and sever-
ity of tuberculosis infection.
Conclusion
In summary, we presented compelling evidence demonstrating
several host genetic factors as important components in
tuberculosis infection. Recent studies targeting candidate genes
and ‘‘case-control’’ associations have revealed numerous
genetic polymorphisms implicated in host susceptibility to
tuberculosis. A number of critical genetic factors will converge
to yield a comprehensive and dynamic representation of tuber-
culosis pathogenesis. Further analysis of the genetic basis of
tuberculosis infection in different populations will likely con-
tribute to the development of new preventative and therapeutic
interventions.
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